| Filed On | Filing |
|---|---|
| 23 Oct 2026 |
Form 3: Carethers John, Director
No securities owned |
| 15 Oct 2026 |
8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
On October 14, 2026, AbbVie Inc. (“AbbVie”) expanded the size of its Board of Directors (the “Board”) from twelve directors to thirteen directors and appointed Dr. John M. Carethers as a Class II director. Dr. Carethers currently serves ... |
| 05 Oct 2026 |
8-K: Results of Operations and Financial Condition
a The Company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the third quarter of 2026, as both cannot be reliably forecasted. |
| 02 Oct 2026 |
Form 4: Quaggin Susan E, Director
Granted 59 Stock Equivalent Units ($15.4K) |
| 02 Oct 2026 |
Form 4: Rapp Edward J, Director
Granted 129 Stock Equivalent Units ($33.7K) |
| 03 Sep 2026 | 8-K: Regulation FD Disclosure |
| 18 Aug 2026 |
Form 4: Donoghoe Nicholas, EVP, CHIEF BUS/STRAT OFFICER
Received 32,710 shares by exercise or conversion ($2.58M) · Sold 32,710 shares ($8.18M) |
| 18 Aug 2026 | 8-K: Other Events |
| 14 Aug 2026 | 144 |
| 06 Aug 2026 | 424B5 |
| 05 Aug 2026 | 8-K: Other Events |
| 05 Aug 2026 | FWP |
| 04 Aug 2026 | 424B5 |
| 03 Aug 2026 | 10-Q |
| 31 Jul 2026 | 8-K: Results of Operations and Financial Condition |
| 06 Jul 2026 | 8-K: Results of Operations and Financial Condition |
| 02 Jul 2026 |
Form 4: Rapp Edward J, Director
Granted 134 Stock Equivalent Units ($33.7K) |
| 02 Jul 2026 |
Form 4: Quaggin Susan E, Director
Granted 62 Stock Equivalent Units ($15.6K) |
| 24 Jun 2026 | 11-K |
| 22 Jun 2026 | 8-K: Regulation FD Disclosure |
Loading...
